A number of other brokerages have also issued reports on GALT. HC Wainwright restated a “buy” rating on shares of Galectin Therapeutics in a research report on Friday, April 1st. Zacks Investment Research raised shares of Galectin Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, January 19th.
Shares of GALT stock opened at $1.46 on Monday. The company has a 50 day moving average price of $1.69 and a 200 day moving average price of $2.13. Galectin Therapeutics has a fifty-two week low of $1.43 and a fifty-two week high of $4.57. The stock has a market capitalization of $86.73 million, a P/E ratio of -2.81 and a beta of 1.64. The company has a debt-to-equity ratio of 79.37, a quick ratio of 4.63 and a current ratio of 4.63.
A number of institutional investors have recently modified their holdings of the business. Virtu Financial LLC purchased a new position in Galectin Therapeutics in the fourth quarter valued at about $37,000. Buckingham Strategic Wealth LLC acquired a new stake in Galectin Therapeutics during the 3rd quarter valued at $42,000. Commonwealth Equity Services LLC increased its stake in shares of Galectin Therapeutics by 59.2% in the first quarter. Commonwealth Equity Services LLC now owns 26,902 shares of the company’s stock worth $43,000 after acquiring an additional 10,000 shares during the last quarter. Raymond James & Associates bought a new stake in shares of Galectin Therapeutics during the 3rd quarter worth about $51,000. Finally, Benjamin F. Edwards & Company Inc. grew its stake in Galectin Therapeutics by 25.5% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 29,615 shares of the company’s stock valued at $61,000 after buying an additional 6,015 shares during the last quarter. 12.35% of the stock is currently owned by institutional investors.
About Galectin Therapeutics (Get Rating)
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.
- Get a free copy of the StockNews.com research report on Galectin Therapeutics (GALT)
- Nasdaq Stock is a Buy the (Deep) Dip Opportunity
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.